{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:20:01Z","timestamp":1790623201256,"version":"4.1.0"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.2169\/internalmedicine.5899-25","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T22:07:09Z","timestamp":1756937229000},"page":"987-996","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Kidney Impairment during Iguratimod Therapy for Rheumatoid Arthritis Patients: The Role of Concomitant Salazosulfapyridine"],"prefix":"10.2169","volume":"65","author":[{"given":"Shunichiro","family":"Hanai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakako","family":"Tanaka-Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yamanashi Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nirasaki Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Nakagomi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lau CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22: 357-375, 2019.","DOI":"10.1111\/1756-185X.13513"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hara M, Abe T, Sugawara S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17: 1-9, 2007.","DOI":"10.1007\/s10165-006-0542-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lu LJ, Bao CD, Dai M, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 61: 979-987, 2009.","DOI":"10.1002\/art.24643"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hara M, Ishiguro N, Katayama K, et al.; Iguratimod-Clinical Study Group. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 24: 410-418, 2014.","DOI":"10.3109\/14397595.2013.843756"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ishiguro N, Yamamoto K, Katayama K, et al.; Iguratimod-Clinical Study Group. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23: 430-439, 2013.","DOI":"10.3109\/s10165-012-0724-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yoshikawa A, Yoshida S, Kimura Y, et al. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: a retrospective study. Mod Rheumatol 28: 227-234, 2018.","DOI":"10.1080\/14397595.2017.1336865"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ebina K, Miyama A, Tsuboi H, et al. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod Rheumatol 29: 581-588, 2019.","DOI":"10.1080\/14397595.2018.1486939"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jiang H, Gao H, Wang Q, Wang M, Wu B. Molecular mechanisms and clinical application of iguratimod: a review. Biomed Pharmacother 122: 109704, 2020.","DOI":"10.1016\/j.biopha.2019.109704"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yan Q, Zhang M, Du F, et al. Efficacy and safety of iguratimod as an add-on therapy for refractory lupus nephritis: a preliminary investigational study. Front Immunol 14: 1062919, 2023.","DOI":"10.3389\/fimmu.2023.1062919"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chen X, Wang W, Xue J. Efficacy and safety of iguratimod combined with celecoxib in active axial spondyloarthritis: a randomized, double-blind, placebo-controlled study. Scand J Rheumatol 53: 420-427, 2024.","DOI":"10.1080\/03009742.2024.2346411"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tang W, Duan H, Lv X, Zhao H, Wu L, Deng X. Long-term effectiveness of the combination of iguratimod and alendronate in SAPHO syndrome: a prospective cohort study. Rheumatology (Oxford) 64: 2842-2846, 2025.","DOI":"10.1093\/rheumatology\/keae641"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mimori T, Harigai M, Atsumi T, et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol 29: 314-323, 2019.","DOI":"10.1080\/14397595.2018.1460230"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nozaki Y, Oribe M, Tomita D, et al. Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: adjusted with propensity score matching. Mod Rheumatol 33: 472-480, 2023.","DOI":"10.1093\/mr\/roac060"},{"key":"14","unstructured":"14. Hasegawa E, Kobayashi D, Ito S, Ishikawa H, Narita I. The influence of iguratimod on renal function. Clinical Rheumatol Relat Res 31: 145-154, 2019 (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.","DOI":"10.1002\/art.1780310302"},{"key":"16","unstructured":"16. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48, 1995.","DOI":"10.1002\/art.1780380107"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ku E, Bakris G, Johansen KL, et al. Acute declines in renal function during intensive BP lowering: implications for future ESRD risk. J Am Soc Nephrol 28: 2794-2801, 2017.","DOI":"10.1681\/ASN.2017010040"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ku E, Tighiouart H, McCulloch CE, et al. Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes. J Am Soc Nephrol 35: 1402-1411, 2024.","DOI":"10.1681\/ASN.0000000000000426"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ku E, Ix JH, Jamerson K, et al. Acute declines in renal function during intensive BP lowering and long-term risk of death. J Am Soc Nephrol 29: 2401-2408, 2018.","DOI":"10.1681\/ASN.2018040365"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ku E, Jamerson K, Copeland TP, McCulloch CE, Tighiouart H, Sarnak MJ. Acute declines in estimated glomerular filtration rate in patients treated with benazepril and hydrochlorothiazide versus amlodipine and risk of cardiovascular outcomes. J Am Heart Assoc 13: e035177, 2024.","DOI":"10.1161\/JAHA.124.035177"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Heerspink HJL, Cherney DZI. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol 16: 1278-1280, 2021.","DOI":"10.2215\/CJN.02480221"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tanaka K, Yamaguchi T, Hara M. Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Rev Clin Immunol 11: 565-573, 2015.","DOI":"10.1586\/1744666X.2015.1027151"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Durando M, Tiu H, Kim JS. Sulfasalazine-induced crystalluria causing severe acute kidney injury. Am J Kidney Dis 70: 869-873, 2017.","DOI":"10.1053\/j.ajkd.2017.05.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal failure. Gut 33: 1006-1007, 1992.","DOI":"10.1136\/gut.33.7.1006"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Akao S, Akao K, Rokutanda R, Suzuki T. Renal perivasculitis induced by sulfasalazine. J Nephrol 37: 1161-1164, 2024.","DOI":"10.1007\/s40620-023-01820-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. H\u00e4mling J, Raedler A, Helmchen U, Schreiber S. 5-aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion 58: 304-307, 1997.","DOI":"10.1159\/000201459"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Linares V, Alonso V, Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert Opin Drug Saf 10: 253-263, 2011.","DOI":"10.1517\/14740338.2011.529898"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Heidari R, Taheri V, Rahimi HR, Shirazi Yeganeh B, Niknahad H, Najibi A. Sulfasalazine-induced renal injury in rats and the protective role of thiol-reductants. Ren Fail 38: 137-141, 2016.","DOI":"10.3109\/0886022X.2015.1096731"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Niknahad H, Heidari R, Mohammadzadeh R, et al. Sulfasalazine induces mitochondrial dysfunction and renal injury. Ren Fail 39: 745-753, 2017.","DOI":"10.1080\/0886022X.2017.1399908"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Heidari R, Rasti M, Shirazi Yeganeh B, Niknahad H, Saeedi A, Najibi A. Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine. Bioimpacts 6: 3-8, 2016.","DOI":"10.15171\/bi.2016.01"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Refaat B, El-Boshy M. Protective antioxidative and anti-inflammatory actions of \u03b2-caryophyllene against sulfasalazine-induced nephrotoxicity in rat. Exp Biol Med 247: 691-699, 2022.","DOI":"10.1177\/15353702211073804"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ 23: 369-379, 2016.","DOI":"10.1038\/cdd.2015.158"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Zhao L, Mu B, Zhou R, Cheng Y, Huang C. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9. Int J Rheum Dis 22: 686-694, 2019.","DOI":"10.1111\/1756-185X.13463"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhou Y, Li Z, Yu S, Wang X, Xie T, Zhang W. Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage-myofibroblast transition. Ren Fail 46: 2327498, 2024.","DOI":"10.1080\/0886022X.2024.2327498"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_5899-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:55:10Z","timestamp":1775274910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_5899-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5899-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"5899-25"}}